The Role of Serum Tetranectin, CA 125, and a Combined Index as Tumor Markers in Women with Pelvic Tumors

Høgdall, Claus; Mogensen, Ole; Tabor, Ann; Mogensen, Bent; Jakobsen, Anders; Nørgaard‐Pedersen, Bent; Larsen, Severin Olesen; Clemmensen, Inge

doi:10.1006/gyno.1995.1004

Cited by 24 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For CA125, markedly elevated median levels were found for the malignant patient groups compared to the benign patient group. For TN, the decreased median levels for each patient group corresponded with previous reports, except for localized OC stage IϩII (Høgdall et al, 1991b(Høgdall et al, , 1995. Normal levels of TN found in localized OCs may reflect smaller tumour volumes in the present patients compared to the other reported studies or a better prognosis for the present patients than in the earlier reported studies, where low TN values were significantly correlated with poor prognosis (Høgdall et al, 1993b).…”

Section: Discussionsupporting

confidence: 86%

“…In Table III, the generally accepted cut-offs for the different markers are used in the calculations of sensitivity and specificity: TN, 7 mg/l (Høgdall et al, 1995); OVX1, 12.1 U/ml (Woolas et al, 1993); CA125, 35 U/ml (Bast et al, 1983); CASA, 6 U/ml (Ward, 1992). Only CA125 had a sensitivity Ͼ60%, whereas the specificities were acceptable for all markers.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Predictive values of serum tumour markers tetranectin, OVX1, CASA and CA125 in patients with a pelvic mass

Høgdall

Tingulstad

et al. 2000

Int. J. Cancer

Self Cite

View full text Add to dashboard Cite

Our objective was to compare the predictive value of the well-established tumour marker CA125 with the newer tumour markers tetranectin (TN), OVX1 and CASA in distinguishing benign and malignant pelvic masses in women. Participants included 185 women, 19 years or older, with a pelvic mass planned for surgical exploration. Significantly different CA125 levels were found between benign tumours and localised ovarian cancer (OC), advanced OC and other non-OCs. Significantly different TN levels were found between benign tumours and advanced OC (stage III/IV), between benign tumours and other cancers and between all OCs and other cancers. For CASA, significant differences were found between benign tumours and all OCs as well as advanced OC. No significant differences could be demonstrated for OVX1. Significant correlations for the 44 OC patients were found between CA125, TN and CASA. No significant correlations were found for OVX1, possibly because of the method used for collection and handling of serum samples. None of the new markers had any additional predictive value compared to CA125. TN and CASA levels correlated with FIGO stage and could be used to discriminate between benign and advanced OC. However, in comparison to the performance of CA125, the additional discriminative value of TN and CASA was minor.

show abstract

Section: Discussionsupporting

confidence: 86%

Section: Resultsmentioning

confidence: 99%

Predictive values of serum tumour markers tetranectin, OVX1, CASA and CA125 in patients with a pelvic mass

Høgdall

Tingulstad

et al. 2000

Int. J. Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…12 Serum levels of CA 125 are reported to be elevated in Ͼ 80% of epithelial OC patients. CA 125 measurement has been reported to be a valuable prognostic marker in various studies of primary OC employing univariate life table analyses, 13,14 but it reportedly loses its independent prognostic value in multivariate analyses when clinical International Federation of Gynecology and Obstetrics (FIGO) stage is included in the model.…”

mentioning

confidence: 99%

Distribution of HER‐2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma

Høgdall

Christensen

Kjær

et al. 2003

Cancer

Self Cite

125

View full text Add to dashboard Cite

BACKGROUNDThe HER‐2 (Human Epidermal Growth factor receptor‐2, also known as c‐erb‐2/neu) protooncogene encodes a transmembrane receptor protein, Mr 185,000. Studies have shown that the HER‐2 oncogene is overexpressed in approximately 25–30% of ovarian carcinoma (OC) cases, but to the authors' knowledge, to date no consensus regarding overexpression and prognosis has been possible. The objective of the current study was first to analyze the presence of HER‐2 overexpression in tissue from Danish OC patients and correlate the distribution of HER‐2 overexpression with clinical and biochemical data and second to investigate the value of HER‐2 overexpression as a prognostic marker in OC and to compare this value with the prognostic value of other biochemical markers.METHODSThe study population was comprised of the first 181 patients diagnosed with epithelial OC who were included in the MALOVA study. The staining procedure for HER‐2 overexpression was performed using the p185 antibody.RESULTSHER‐2 overexpression was found in 95 of the 181 investigated cases (52.5%), in which 71 carcinomas (39.2%) were weakly positive (1+) and 24 carcinomas (13.3%) were moderately (2+) to intensely positive (3+). Increased HER‐2 expression was found to be correlated with reduced survival. Significant differences in survival between patients with (1+, 2+, and 3+) and those without HER‐2 overexpression were found for patients with International Federation of Gynecology and Obstetrics (FIGO) Stage I, Stage III, and Stage III/IV OC (Stage I: P = 0.021; Stage III: P = 0.0078; and Stage III/IV: P = 0.0054). Multivariate survival analyses including all 181 OC patients demonstrated that HER‐2 overexpression is a prognostic marker (P = 0.003) together with disease stage, serum tetranectin level, and patient age. For patients with Stage III OC, the only independent prognostic factors detected were HER‐2 overexpression (P = 0.009) and serum tetranectin level (P ≤ 0.0001).CONCLUSIONSThe results of the current study show that HER‐2 overexpression has prognostic value both in univariate and multivariate survival analyses. Therefore, the clinical relevance of this observation should be established conclusively by therapy that targets HER‐2 in a prospective Phase II clinical trial. Cancer 2003;98:66–73. © 2003 American Cancer Society.DOI 10.1002/cncr.11476

show abstract

“…18 Several investigators have reported that plasma and serum TN concentrations in patients with malignant tumours correlate with disease stage and survival. [19][20][21][22][23][24][25][26] Others found that TN expression in tumour tissue correlated with tumour histological grading. 27 The aim of our study was to evaluate the expression of TN in breast cancer tissue and in adjacent normal breast tissue and to investigate its role as a prognostic marker.…”

mentioning

confidence: 99%

Aberrant tetranectin expression in human breast carcinomas as a predictor of survival

Obrist

Spizzo²,

Ensinger³

et al. 2004

Journal of Clinical Pathology

View full text Add to dashboard Cite

The Role of Serum Tetranectin, CA 125, and a Combined Index as Tumor Markers in Women with Pelvic Tumors

Cited by 24 publications

References 0 publications

Predictive values of serum tumour markers tetranectin, OVX1, CASA and CA125 in patients with a pelvic mass

Predictive values of serum tumour markers tetranectin, OVX1, CASA and CA125 in patients with a pelvic mass

Distribution of HER‐2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma

Aberrant tetranectin expression in human breast carcinomas as a predictor of survival

Contact Info

Product

Resources

About